Microglia are an important cellular target in a range of neurodegenerative diseases such as multiple sclerosis and spinal cord injury.
At Aquila, we offer a suite of microglia assays to better understand the MOA of your drug candidate and its potential to enhance the restorative role of activated microglia, de-risking your early discovery program.
We offer monoculture assays using primary cells or cell lines as well as co-culture assays. These assays are ideal for medium-throughput screening and pre-clinical optimisation. Working in collaboration with you, we can assess your compound’s ability to dampen the M1 pro-inflammatory response or promote the M2 effector function of activated microglia, identifying molecules that drive repair or enhance resilience of CNS tissue. Depending on the nature of the compound, we can include a combination of both assessments to investigate the M1 to M2 switch.
To progress your drug discovery program further, we offer an ex vivo brain slice model as a translational link between in vitro and in vivo studies. To find out more click here.
Our scientific team are experts in glial cell biology and work closely with you to customise your program, supporting your best route to clinic.
Please get in touch to find out more about our microglia cell related services.